This evidence emphasizes the tumor‐suppressive role of miR‐30e‐3p in GC and supports its use as a biomarker and therapeutic agent via modulation of the THOC2/PI3K/AKT/mTOR. The gene discussed is AKT1; the disease is neoplasm.